

10/776, 002

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("20040063715").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:31
L2	1	("20040072835").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:31
L3	1	("20040220189").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:32
L4	1	("20050009832").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:32
L5	1	("20050054649").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:32
L6	1	("20050085484").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:33
L7	1	("20050090499").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:33
L8	1	("20050101604").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:34
L9	1	("20050288295").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 10:16
L10	1	("7015227").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 10:17
L11	1	("6919340").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 10:33
L12	480	544/350	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/03/24 11:26
L13	90	l12 and (kinase or ephb4 or vegf-r2 or tie-2)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/03/24 11:27
L14	91	l12 and (kinase or ephb4 or vegf-r2 or tie-2)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/03/24 11:27
L15	14	l14 and imidazo[1,2-a]pyrazine	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/03/24 11:27

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAL623ZCT


PASSWORD:DDSA4KNB

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'REGISTRY' AT 11:11:31 ON 24 MAR 2006
FILE 'REGISTRY' ENTERED AT 11:11:31 ON 24 MAR 2006
COPYRIGHT (C) 2006 American Chemical Society (ACS)
ENTER LOGIC EXPRESSION OR (END):end

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\Stnexp\Queries\10776002 KINASE INHS.str



Chain nodes :
10 11 12
Ring nodes :
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
Chain bonds :
1-10 2-13 4-12 8-11
Ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 1-10 2-3 2-13 3-4 4-5 4-12 5-6 5-7 6-9 7-8 8-9 8-11 13-14 13-18 14-15 15-16 16-17 17-18

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
Generic attributes :
12: : Unsaturated
Type of Ring System : Monocyclic

L4 STRUCTURE UPLOADED


=> que L4

L5 QUE L4

=> d L4

L4 HAS NO ANSWERS

STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s L4
SAMPLE SEARCH INITIATED 11:14:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2735 TO ITERATE

73.18 PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
PROJECTED ITERATIONS: BATCH 51564 TO 57836
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L4

=> s L4 sss full
FULL SEARCH INITIATED 11:14:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 55616 TO ITERATE

100.08 PROCESSED 55616 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L7 2 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY 173.98
TOTAL SESSION 180.79

STN SEARCH TRANSCRIPT
10/776,002

FILE 'CAPLUS' ENTERED AT 11:14:46 ON 24 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETTERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STM. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Mar 2006 VOL 144 ISS 14
FILE LAST UPDATED: 23 Mar 2006 (20060323/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 17
L8 2 L7
=> d 1-2 bib abs

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STM
ACCESSION NUMBER: 1971:125628 CAPLUS
DOCUMENT NUMBER: 74:125628
TITLE: New method for synthesizing pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a]quinolines
AUTHOR(S): Shvedov, V. I.; Alukhova, L. B.; Grinev, A. N.
CORPORATE SOURCE: Vses. Nauchno-Issled. Khim.-Farm. Inst. im. Ordzhonikidze, Moscow, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), (8), 1048-50
CODEN: KGSMAQ; ISSN: 0132-6244

DOCUMENT TYPE: Russian
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB Alkylation of Na derivs. of 2-acylpyrroles with acetals of α -bromo carbonyl compds., followed by reaction with NH_4OAc in HOAc gave pyrrolo[1,2-a]pyrazines (I). Thus, 19 g 2-formylpyrrole in dioxane was treated with alc. NaOEt and then with 50.6 g $\text{BrCH}_2\text{CH}(\text{OBU})_2$ in DMF. The product was refluxed with 150 g NH_4OAc in HOAc to give 8 g I (R = R1 = R2 = R3 = R4 = H). The following I were prepared (R, R1, R2, R3, and R4 given): H, Me, COEt, Me, Me; H, H, H, H, Ph; H, H, H, H, Ph. Similarly, alkylation of 8.5 g 2-benzoylpyrrole with 11.2 g α -bromocyclohexanone dimethyl ketal, followed by heating with 40 g NH_4OAc , gave 7 g IV, which was refluxed with Ni in xylene to give 96% V.
L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STM
ACCESSION NUMBER: 1969:413142 CAPLUS
DOCUMENT NUMBER: 71:13142
TITLE: Derivative of pyrrolo[1,2-a]pyrazine
INVENTOR(S): Shvedov, V. I.; Alukhova, L. B.; Bocharnikova, A. V.; Grinev, A. N.
PATENT ASSIGNEE(S): Ordzhonikidze, S., All-Union Scientific-Research Chemical-Pharmaceutical Institute
SOURCE: U.S.S.R. From: Otkrytiya, Izobretya, Prom. Obratstvy, Tovarnye Znaki 1969, 46(8), 22.

DOCUMENT TYPE: CODEN: URXXAF
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 1 Russian
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 237153	---	19690212	SU	19671201
GI	---	---	---	---
AB	---	---	---	---

The title compound (I, R1, R2, R3, R4, and R5 = H, and alkyl, or an aryl) is prepared by reacting the Na derivative of 2-acylpyrrole with an α -bromocarbonyl compound or its acetal. The dicarbonyl derivative obtained is treated with NH_4OAc in boiling HOAc.

=> d 1-2 hitstr
'1-2' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AL, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCI, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS
IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels
OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OIBIB, indented with text labels
SBIB ----- BIB, no citations
SIBIB ----- BIB, no citations
HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCI, CC and index field (ST and IT)
HITRN ----- HIT RN and its text modification
HITRNR ----- HIT RN, its text modification, its CA index name, and its structure diagram
HITSEO ----- HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
HITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
HITSEPO ----- First HIT RN, its text modification, its CA index name, its

structure diagram, plus NTE and SPO fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDs at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.


All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, HITSTR, HITSEQ, HITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
 ENTER DISPLAY FORMAT (BIB):end

=> d 1-2 hitstr

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 IT 24608-67-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

RN 24608-67-1 CAPLUS
 CN Pyrolo[1,2-a]pyrazine, 1,3-diphenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)




● HCl

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 IT 24608-67-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

RN 24608-67-1 CAPLUS
 CN Pyrolo[1,2-a]pyrazine, 1,3-diphenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl

=> file reg
 COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST ENTRY SESSION
 11.14 191.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
 CA SUBSCRIBER PRICE ENTRY SESSION
 -1.50 -1.50

FILE 'REGISTRY' ENTERED AT 11:16:02 ON 24 MAR 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAR 2006 HIGHEST RN 877759-05-2
 DICTIONARY FILE UPDATES: 22 MAR 2006 HIGHEST RN 877759-05-2

New CAS Information Use Policies, enter HELP USAGETERMS for details:
 TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERI, is now *
 * available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
 Uploading C:\Program Files\Stnexp\Queries\10776002 KINASE INHS.str



chain nodes :
 10 11 12
 ring nodes :
 1 2 3 4 5 6 7 8 9 13 14 15 16 17 18
 chain bonds :
 1-10 2-13 4-12 8-11
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
 17-18
 exact/norm bonds :
 1-2 1-6 1-10 2-3 2-13 3-4 4-5 4-12 5-6 5-7 6-9 7-8 8-9 8-11 13-14
 13-18 14-15 15-16 16-17 17-18

G1:C,N

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
 Generic attributes :
 12:
 Saturation : Unsaturated
 Type of Ring System : Monocyclic

L9 STRUCTURE UPLOADED


=> que L9

L10 QUE L9

=> d 19

L9 HAS NO ANSWERS

L9 STR



Monocyclic, unsaturated, not OR ORBO -

CORRECT STRUCTURE

Structure attributes must be viewed using STN Express query preparation.

=> s 19
 SAMPLE SEARCH INITIATED 11:16:22 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 637 TO ITERATE
 100.0% PROCESSED 637 ITERATIONS
 SEARCH TIME: 00.00.01 5 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 11226 TO 14254
 PROJECTED ANSWERS: 5 TO 234

L11 5 SEA SSS SAM L9

=> s 19 sss full
 FULL SEARCH INITIATED 11:16:27 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 12382 TO ITERATE
 100.0% PROCESSED 12382 ITERATIONS
 SEARCH TIME: 00.00.01 77 ANSWERS

L12 77 SEA SSS FULL L9

=> file caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE
 SINCE FILE
 ENTRY 166.94
 TOTAL
 ENTRY 358.87
 TOTAL
 ENTRY -1.50

FILE 'CAPLUS' ENTERED AT 11:16:32 ON 24 MAR 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STM. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Mar 2006 VOL 144 ISS 14
FILE LAST UPDATED: 23 Mar 2006 (20060323/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L12

L13 3 L12

=> d 1-3 ldlb abs hitstr

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STM

ACCESSION NUMBER: 2005:295613 CAPLUS

DOCUMENT NUMBER: 142:482014

TITLE:

Synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivatives by using either reflux or microwave irradiation method and investigation of their anticancer activities

Demirayak, Serref; Kayaçil, Ismail

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, 26470, Turk.

Journal of Heterocyclic Chemistry (2005), 42(2),

319-325

CODEN: JHRCAD; ISSN: 0022-152X

Heterocorporation

Journal

English

CASREACT 142:482014


PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S):

GI



AB The preparation of 6,8-diarylimidazo[1,2-a]pyrazines, e.g. I, via the reaction of 1-(2-aryl-2-oxoethyl)-2-arylimidazole derivs., e.g. II, with ammonium acetate in acetic acid utilizing a new method, is reported.

Anticancer activities of the compds. obtained were evaluated and the activity values were reported.

IT 852101-80-5P 852101-81-6P 852101-84-9P

852101-85-0P 852101-86-1P 852101-87-2P

852101-89-4P 852101-90-7P 852101-91-8P

852101-92-9P 852101-93-0P


RI: PNC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PNEP (Preparation)

(Synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivs. by using either reflux or microwave irradiation method and investigation of their anticancer activities)

852101-80-5 CAPLUS


852101-84-9 CAPLUS

Imidazo[1,2-a]pyrazine, 6-(4-methoxyphenyl)-8-phenyl- (9CI) (CA INDEX NAME)




RN 852101-81-6 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-phenyl- (9CI) (CA INDEX NAME)




RN 852101-84-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-(4-methoxyphenyl)-8-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 852101-85-0 CAPLUS


CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 852101-86-1 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 852101-87-2 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-methoxyphenyl)-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 852101-89-4 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 852101-90-7 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 852101-91-8 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 852101-92-9 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 852101-93-0 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6,8-bis(4-chlorophenyl)- (9CI) (CA INDEX NAME)




IT 852101-63-4P 852101-79-2P 852101-82-7P


852101-83-8P 852101-88-3P
RT: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivative by using
ether reflux or microwave irradiation method and investigation of their
anticancer activities)
RN 852101-63-4 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6,8-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 852101-79-2 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-(4-methylphenyl)-8-phenyl- (9CI) (CA INDEX NAME)




RN 852101-82-7 CAPLUS
CN Imidazo[1,2-a]pyrazine, 8-(4-methylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 852101-83-8 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6,8-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 852101-88-3 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6,8-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 50

THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

113 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 20041686382 CAPLUS
DOCUMENT NUMBER: 1411225338
TITLE: Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines
as modulators of kinase activity, particularly EphB4
kinase, and their preparation, pharmaceutical
compositions, and methods of use for modulation and

APPLICANTS


[illegible]

APPLICANTS


comps., and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including breast neoplasms, endometrial cancer, colon cancer, and neck squamous cell carcinoma. The methods of treatment include administering a sufficient amount of I or a salt to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to EphB4 modulation. Methods of treatment include administering I as a single active agent or administering a compound I in combination with one or more other therapeutic agents. The invention also includes a method for determining the presence of EphB4 kinase in a sample, comprising contacting the sample with a compound I, or form thereof, and detecting the amount of compound or form bound to EphB4 kinase, and therefrom determining the presence or absence of EphB4 kinase in the sample. Ten comps. I were prepared in examples. For instance, compound II was prepared in 4 steps: (1) deprotection of BrICH2CH(OMe)2 with HBr and cyclocondensation with 3,5-dibromo-2-aminopyrazine to give 6,8-diimidazo[1,2-a]pyridine; (2) amination of the 6-bromo with 4-(1H-imidazo[1,2-y])pyridine; (3) Suzuki coupling of the 8-bromo with 3-HZNC6H4B(OH)2.HCl; and (4) carbamoylation of the amino group with 2-isocyanato-1-methoxy-4-(trifluoromethyl)benzene. In an assay for EphB4 kinase activity, using human recombinant EphB4 kinase cytoplasmic domain (Genbank Accession Number AY056047), comps. I had IC50 values of 10 μ M or less, with some particularly preferred comps. having values of 100 nM or less. Similar inhibitory potencies were found against VEGF-R2, c-Klt, and Tie-2 kinases *in vitro*.

IT
746642-12-0P, 1-(2-Methoxy-5-trifluoromethylphenyl)-3-[3-(8-12-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-13-0P, 1-(4-Methoxy-3-trifluoromethylphenyl)-3-[3-(8-12-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-14-0P, 1-(2-Methoxy-5-trifluoromethylphenyl)-3-[3-(8-12-pyridin-3-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-15-0P, 1-(5-Chloro-2-methoxyphenyl)-3-[3-(8-12-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-16-0P, 1-(5-Fluoro-2-trifluoromethylphenyl)-3-[3-(8-12-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-17-1P, 1-(5-Chloro-2-trifluoromethylphenyl)-3-[3-(8-12-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-18-0P, 1-(5-Chloro-2-4-di(methoxy)phenyl)-3-[3-(8-12-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-19-3P, 1-(4-Methyl-3-trifluoromethylphenyl)-3-[3-(8-12-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-20-0P, 1-(4-Chloro-3-trifluoromethylphenyl)-3-[3-(8-12-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
746642-21-1P, 1-(2-Methoxy-5-trifluoromethylphenyl)-3-[3-(8-13-pyridin-4-yl)imidazol-1-yl]imidazol-1-yl-2-*a*-pyrazin-6-yl]phenyl]urea
R1: PIC (Pharmacological activity): SP (Synthetic preparation): THU (Therapeutic use): B10L (Biological study): PEP (Preparation): USSS (Uses)
(Drug candidate; preparation of heteroarylphenylimidazopyrazines as kinase modulators for treatment of cancer and angio genesis)
746642-12-6 CAPUS
Urea, N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-[3-(8-12-(4-pyridinyl)-1H-


imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-13-7 CAPLUS
CN Urea, N-[4-methoxy-3-(trifluoromethyl)phenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-14-8 CAPLUS
CN Urea, N-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-15-9 CAPLUS
CN Urea, N-[5-chloro-2-methoxyphenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-16-0 CAPLUS
CN Urea, N-[5-fluoro-2-(trifluoromethyl)phenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-17-1 CAPLUS
CN Urea, N-[5-chloro-2-(trifluoromethyl)phenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-18-2 CAPLUS
CN Urea, N-[5-chloro-2,4-dimethoxyphenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-19-3 CAPLUS
Urea, N'-[4-methyl-3-((trifluoromethyl)phenyl)-N'-[3-(8-(2-(4-pyridinyl))-1H-imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-20-6 CAPLUS
Urea, N'-[4-chloro-3-((trifluoromethyl)phenyl)-N'-[3-(8-(2-(4-pyridinyl))-1H-imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-21-7 CAPLUS
Urea, N'-[2-methoxy-5-((trifluoromethyl)phenyl)-N'-[3-(8-(2-(4-pyridinyl))-1H-imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



IT 746642-23-9P, 3-(8-(2-(pyridin-4-yl)]imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenylamine
Rt: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Intermediate; preparation of heteroarylphenylimidazopyrazines as kinase modulators for treatment of cancer and angiogenesis)
RN 746642-23-9 CAPLUS
Benzamide, 3-(8-(2-(4-pyridinyl))-1H-imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX NAME)




L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:696381 CAPLUS
DOCUMENT NUMBER: 141:225537
TITLE: Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity and their preparation, pharmaceutical compositions, and methods of use

INVENTOR(S): Currie, Kevin S.; Desimone, Robert W.; Pippin, Douglas A.; Darrow, James W.; Mitchell, Scott A.
PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072080	A1	20040826	WO 2004-US3922	20040210
W: AE, AE, AG, AL, AL, AM, AM, AT, AU, AU, AZ, BA, BB, BG,				

BG, BR, BR, BM, BY, BZ, BZ, CA, CH, CN, CO, CO, CR, CR,
 CU, CZ, CZ, DE, DE, DE, DE, DE, DE, DE, DE, DE, DE,
 ES, FI, FI, GB, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE,
 IS, JP, JP, KE, KE, KE, KE, KE, KE, KE, KE, KE, KE,
 LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MD, MD, MD, MD,
 MK, MG, NA, NI
 RM: BW, CH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZM, AT, BE,
 BG, CH, CY, CZ, DE, DE, DE, DE, DE, DE, DE, DE, DE, DE,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GO, GM, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
 GO, GM, ML, MR, NE, SN, TD, TG
 US 2005054648 A1 20050310 US 2004-776002 20040210
 US 2005054649 A1 20050310 US 2004-776633 20040210
 PRIORITY APPN. INFO.: US 2003-446379P P 20030210
 OTHER SOURCE(S): MARPAT 141:225537




AB The invention pertains to compds. I and all pharmaceutically acceptable forms thereof [wherein: R1 = H, halo, alkyl, alkoxy, (hetero)cycloalkyl(alkyl), sulfonamide, alkoxyalkyl, alkoxyalkoxy, (di)alkylamino(alkyl); or R1 = Ph or a benzo-fused 5- to 7-membered N/O/S heterocycloalkyl bearing 0-3 selected substituents; W = Ph or 5- or 6-membered N/O/S heteroaryl with 1-4 heteroatoms and 0-3 selected substituents; X = N or CH; R2 = (alkoxy)alkyl, (hetero)cycloalkyl(alkyl), (alkoxy)alkoxy; or R2 = phenyl(alkyl) or heteroaryl(alkyl) bearing 0-3 selected substituents; 2 = (CR8R9)n, CONR10, NR10CO, or NR10CONR11; R8, R9 = H, alkyl, alkoxy, halo; n = 0-2; R10, R11 = H, alkyl; or Ph or heteroaryl with 0-3 selected substituents; R3 = H, alkyl; or R3 = (hetero)cycloalkyl(alkyl), Ph, or heteroaryl each bearing 0-3 selected substituents; or R3 = phenoxyphenyl with each ring bearing 0-3 selected substituents]. Addnl. compds. with a linking group between R1 and W are disclosed but neither prepared nor claimed. The compds. I are modulators of kinase activity and Hsp90 complex activity. Certain compds. I are highly active inhibitors of Hsp90 complex activity. The invention also provides pharmaceutical compds. containing one or more compound I, or a pharmaceutically acceptable form of such compds., and one or more pharmaceutically


acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases. The methods of treatment include administering a sufficient amount of a compound I or a form thereof to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating non-human patients, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to Hsp90 complex modulation. Methods of treatment include administering a compound I as a single active agent or administering a compound I in combination with one or more other therapeutic agents. The invention also includes a method for determining the presence of certain

kinases
 or Hsp90 complex in a sample, comprising contacting the sample with a compound I, or form thereof, and detecting Hsp90 complex activity in the sample. Almost 50 compds. I were prepared in examples. For instance, compound II was prepared in 4 steps: (1) deprotection of BIC2CH(OEt)2 with HBr and cyclocondensation with 3,5-dibromo-2-aminopyrazine to give 6,8-dibromimidazolidol-1,2-a)pyrazine; (2) aminolysis of the 8-bromo with 4-(p-tolyl)-1H-imidazole; (3) Suzuki coupling of the 6-bromo with 3-H2NC6H4(OH)2.HCl; and (4) carbamoylation of the amino group with 1-isocyanato-2-methylbenzene. In a tumor cell monolayer proliferation assay using MCF-7 or HCT-15 cells, compds. I had IC50 values of 25 μ M or less, with certain compds. having values of 10 μ M or less.


IT
 746653-81-6P, 1-[3-(8-(4-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-82-7P, 1-(4-chlorophenyl)-3-[3-(8-(4-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-83-8P, 1-(2-methylsulfonylphenyl)-3-[3-(8-(4-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-84-9P, 1-[3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-85-0P, 1-(4-chlorophenyl)-3-[3-(8-(4-4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-86-1P, 1-[3-(8-(4-(4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-87-2P, 1-(4-chlorophenyl)-3-[3-(8-(4-p-tolylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-88-3P, 1-o-tolyl-3-[3-(8-(4-p-tolylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-89-4P, 1-(4-chlorophenyl)-3-[3-(8-(4-methylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-90-7P, 1-(3-chloro-4-fluorophenyl)-3-[3-(8-(4-(4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-91-8P, 1-(3-chloro-4-fluorophenyl)-3-[3-(8-(4-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-92-9P, 1-(3-(8-(4-(4-methylpiperazin-1-yl)methyl)phenyl)urea 746653-93-0P, 1-[3-(8-(4-(4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-(4-(4-morpholin-4-yl)methyl)phenyl]urea 746653-94-1P, 1-[3-(8-(4-(4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-(4-((3-ethoxypropyl)amino)methyl)phenyl]urea 746653-95-2P, 1-(4-chlorophenyl)-3-[3-(8-(3-phenylpyrazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-96-3P, 1-(3-chloro-4-fluorophenyl)-3-[3-(8-(3-phenylpyrazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-97-4P, 1-(3-chloro-4-fluorophenyl)-3-[3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-98-5P, 4-chloro-N-(3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl)phenyl]benzamide 746653-99-6P, 3-(morpholin-4-yl)methyl-N-(3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl)phenyl]benzamide 74654-00-2P, 4-(morpholin-4-yl)methyl-N-(3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl)phenyl]benzamide 74654-01-3P,




RN	CAPLUS
746653-85-0	Urea, N'-(4-chlorophenyl)-N'-[3-{8-[4-(4-chlorophenyl)-1H-imidazo[1,1-y]imidazo[1,2-a]pyrazin-6-yl]phenyl}-(9CI) (CA INDEX NAME)




RN	74653-86-1	CAPLUS
CN	Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-(2-methylphenyl)-(9CI)	(CA INDEX NAME)




RN	74653-87-2	CAPLUS
CN	Urea, N-(4-chlorophenyl)-N'-[3-[8-(4-(4-methylphenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-(9CI)	(CA INDEX NAME)




RN	746653-88-3	CAPLUS
CN	Urea, N-(2-methylphenyl)-N'-[3-[8-(4-(4-methylphenyl)-1H-imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI)	(CA INDEX NAME)




RN	746653-89-4	CAPLUS
CN	Urea, N-(4-chlorophenyl)-N'-[3-[8-(4-methyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI)	(CA INDEX NAME)




RN	746653-90-7	CAPLUS
CN	Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-(8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl)phenyl]-(9cI)	(CA INDEX NAME)




RN 74653-91-8 CAPIUS
CN Urea, N-[(3-chloro-4-fluorophenyl)-N'-(3-{8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N-(4-{4-morpholinylmethyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 74653-92-9 CAPIUS
CN Urea, N-[(3-{8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N'-(3-{8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N-(4-{4-methyl-1-piperazinylmethyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 74653-93-0 CAPIUS
CN Urea, N-[(3-{8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N'-(3-{8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N-(4-{4-morpholinylmethyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 74653-94-1 CAPIUS
CN Urea, N-[(3-{8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N'-(3-{8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N-(4-{4-morpholinylmethyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 74653-95-2 CAPIUS
CN Urea, N-[(3-chloro-4-fluorophenyl)-N'-(3-{8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N-(4-{4-morpholinylmethyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 746653-96-3 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-(3-[8-(3-phenyl-1H-pyrazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746653-97-4 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746653-98-5 CAPLUS
CN Benzamide, 4-chloro-N-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746653-99-6 CAPLUS
CN Benzamide, 3-(4-morpholinylmethyl)-N-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746654-00-2 CAPLUS
CN Benzamide, 4-(4-morpholinylmethyl)-N-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746654-01-3 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-(3-[8-(2-(4-methylphenyl)-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746654-02-4 CAPLUS
CN Urea, N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazol-1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-03-5 CAPLUS
CN Urea, N-[4-(4-morpholinylmethyl)phenyl]phenyl]-N'-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-04-6 CAPLUS
CN Imidazol[1,2-a]pyrazine, 6-[4-(4-morpholinylmethyl)phenyl]-8-(2-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 746654-05-7 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(2-(2-methylphenyl)-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-06-8 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-(2-(2-methylphenyl)-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-07-9 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(2-(2-methoxyphenyl)-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-08-0 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(2-(2-fluorophenyl)-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-09-1 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-(8-[2-(2-fluorophenyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-10-4 CAPLUS
CN Urea, N-[3-(8-[2-(2-fluorophenyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-11-5 CAPLUS
CN Urea, N-[3-(8-[2-(2-methoxyphenyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-12-6 CAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-(8-[2-(1-methylethyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-13-7 CAPLUS
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-(8-[2-(1-methylethyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-14-8 CAPLUS
CN Urea, N-[3-(8-[4-bromo-1H-imidazol-1-yl]imidazol-1,2-a]pyrazin-6-yl]phenyl]-N'-[4-chlorophenyl]- (9CI) (CA INDEX NAME)




RN 746654-15-9 CAPLUS
CN Benzamide, 4-fluoro-N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-16-0 CAPLUS
CN Benzamide, 3-methoxy-N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-17-1 CAPLUS
CN Benzamide, 3-methoxy-4-methyl-N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-18-2 CAPLUS
CN Benzamide, N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-19-3 CAPLUS
CN Benzamide, 2,6-dimethyl-N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-20-6 CAPLUS
CN Benzamide, 4-fluoro-N-[3-(8-(2-(4-methylphenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-21-7 CAPIUS
CN Benzamide, 3-methoxy-N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-22-8 CAPIUS
CN Benzamide, 3-methoxy-N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-23-9 CAPIUS
CN Benzeneacetamide, 4-chloro-N-[3-[8-[2-phenyl-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-24-0 CAPIUS
CN Benzeneacetamide, 4-chloro-N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 746654-25-1 CAPIUS
CN Benzeneacetamide, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 746654-26-2 CAPIUS
CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-27-3 CAPIUS
CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 746654-28-4 CAPIUS


CN Urea, N-[3-[8-(2-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-[(4-methyl-1-piperazinyl)methyl]phenyl] - (9CI) (CA INDEX NAME)



IT 746654-30-8P, 3-[8-(4-p-Tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Intermediate; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)
 RN 746654-30-8 CAPUS
 CN Benzenamine, 3-[8-[4-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl] - (9CI) (CA INDEX NAME)



IT 746654-31-9, 3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine
 RI: RCT (Reactant); RACT (Reactant or reagent)
 (Starting material; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)
 RN 746654-31-9 CAPUS
 CN Benzenamine, 3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl] - (9CI) (CA INDEX NAME)



=> log hold
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE
 SESSION WILL BE HELD FOR 60 MINUTES
 STM INTERNATIONAL SESSION SUSPENDED AT 11:21:08 ON 24 MAR 2006

SINCE FILE ENTRY	TOTAL SESSION
19.01	377.88
-2.25	
-3.75	